Cara Therapeutics | CARA

Peers Price Chg Day Year Date
Chugai Pharma 6,678.00 63.00 0.95% 2.00% Sep/08
Acadia Pharmaceuticals 25.40 0.14 0.55% 61.07% Sep/08
Clal Biotechnology 32.00 0.40 1.27% -17.53% Sep/04
Compugen 479.60 -2.50 -0.52% -33.09% Sep/04
Cipla 1,544.40 -9.00 -0.58% -4.68% Sep/08
CSL 213.37 4.12 1.97% -28.97% Sep/08
Grifols 10.13 0.23 2.32% 19.32% Sep/05
Halozyme Therapeutics 75.94 1.01 1.35% 28.26% Sep/08
J&J 178.35 -0.08 -0.04% 7.03% Sep/08
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Pacira 26.18 -0.27 -1.02% 89.03% Sep/08
Pfizer 24.57 -0.31 -1.25% -14.03% Sep/08
Cassava Sciences 2.13 -0.03 -1.39% -92.08% Sep/08
RedHill Biopharma 1.43 0.20 16.54% -84.72% Sep/05
Supernus Pharmaceuticals 46.00 0.57 1.25% 35.93% Sep/05

Indexes Price Day Year Date
USND 21830 129.66 0.60% 29.29% Sep/08
US2000 2388 -2.90 -0.12% 13.84% Sep/08

Cara Therapeutics traded at $0.83 this Tuesday April 9th, increasing $0.01 or 0.79 percent since the previous trading session. Looking back, over the last four weeks, Cara Therapeutics gained 12.41 percent. Over the last 12 months, its price fell by 81.95 percent. Looking ahead, we forecast Cara Therapeutics to be priced at 0.83 by the end of this quarter and at 0.80 in one year, according to Trading Economics global macro models projections and analysts expectations.

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.